多发性骨髓瘤患者血清可溶性细胞间黏附分子-1水平检测及临床意义

目的探讨多发性骨髓瘤（MM）患者血清可溶性细胞间黏附分子-1（sICAM-1，CD54）水平的临床价值。方法采用酶联免疫吸附法（ELISA）测定多发性骨髓瘤患者治疗前后血清sICAM-1水平，并与同期健康体检者32例对照。结果对照组血清sICAM-1水平为（287±82）μg／L，MM患者治疗前血清sICAM-1水平为（374±101）μg／L，两组间差异有统计学意义（P〈0．05）。4个VAD方案化疗后缓解26例，其血清sICAM-1水平为（298±51）μg／L，与对照组比较差异无统计学意义（P〉0．05）；未缓解的12例患者血清sICAM-1水平为（3344±89）μg／L，与缓解MM患者比较差异有统计学意义（P〈0．05）。在观察期内有15例患者复发，其血清中sICAM-1水平为（352±113）μg／L，与缓解期比较差异有统计学意义（P〈0．05）。不同临床分期MM患者血清sICAM-1水平间差异有统计学意义（P〈0．05）；且Ⅲ期患者与Ⅰ期、Ⅱ期患者血清sICAM-1水平间差异均有统计学意义（P〈0．05）；Ⅰ期与Ⅱ期患者血清sICAM-1水平间差异均有统计学意义（P〈0．05）。结论血清sICAM—1水平的检测对多发性骨髓瘤患者的诊断、疗效判定及预后有一定帮助。

The Detection and Clinlc Significance of Serum sICAM-1 Levels in Multiple Myeloma Patients

Objective To explore the clinic significance of sICAM - 1 in patients with multiple myeloma by investigating its serum levels. Methods Serum levels of sICAM - 1 were measured with enzyme linked immunosorbent assay （ELISA）. Results Serum levels of sICAM - 1 in multiple myeloma patients elevated significantly compared with normal control group （ P 〈0. 01） and reduced to normal levels after remission. Serum levels of sICAM - 1 in relapsed multiple myeloma patients also elevated significantly compared with normal control group （ P 〈0. 01 ）. At m stage patients were higher obviously than that at Ⅱ satge and Ⅰ stage （ P 〈 0. 05, P 〈 0. 01 ）. Conclusion It has a certain help to measure serum levels of sICAM - 1 in multiple myeloma patients for diagnosis and judging the development of clinical status, treatment outcome and prognosis.